Graham J J, Wise P H, Harding P E
Med J Aust. 1977 Jul 23;2(4):113-6. doi: 10.5694/j.1326-5377.1977.tb99083.x.
In three cases of established cranial diabetes insipidus, the effectiveness of the new vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVP) in controlling diabetes insipidus is demonstrated. A single dose of 20 micrograms of DDAVP given intranasally had an antidiuretic action from 16 to 24 hours in the three cases, and 10 micrograms given twice daily intranasally was effective in controlling the diabetes insipidus with no side effects. All the patients preferred this form of therapy to their previous treatment.
在3例确诊的颅咽管型尿崩症患者中，证实了新型血管加压素类似物1-去氨基-8-D-精氨酸血管加压素（DDAVP）控制尿崩症的有效性。3例患者经鼻内给予单剂量20微克DDAVP后，抗利尿作用持续16至24小时，经鼻内每日两次给予10微克DDAVP可有效控制尿崩症，且无副作用。所有患者均更喜欢这种治疗方式而非他们之前的治疗。
